Cardiovascular & Longevity

NAD+ and Parkinson’s: What the Trials Found (2026)

No approved treatment raises NAD+ to slow, stop, or reverse Parkinson’s disease. The completed randomized trials of NAD+ precursors in Parkinson’s were…

BPC-157 for Joint Pain: What the Evidence Shows (2026)

BPC-157 is not an established treatment for joint pain or inflammation, and no regulator has approved it for any indication. Nearly all…

What Is Vesugen? The Vascular Bioregulator Peptide Explained

Livagen is a short “bioregulatory” peptide (sequence: Lys–Glu–Asp–Ala; alias KEDA) studied for its ability to loosen age‑condensed chromatin and normalize

What is PNC-27? The Anti-Cancer Peptide Explained

PNC-27 is a synthetic 32-amino-acid peptide that, in cell-culture and mouse studies, appears to punch holes in the membranes of cancer cells…

What is Livagen? Mechanism, Benefits, Dosage & More

Livagen is a synthetic tetrapeptide bioregulator (sequence Lys–Glu–Asp–Ala, abbreviated KEDA) developed within the Russian “Khavinson school” of short peptide research, and the…